Global Vertigo Drugs Market 2019-2023; Led by F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Pfizer, and Teva Pharmaceutical Industries - ResearchAndMarkets.com

DUBLIN--()--The "Global Vertigo Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The vertigo drugs market will register a CAGR of close to 4% by 2023.

Vertigo mostly occurs due to inner ear infections or other conditions such as benign paroxysmal positional vertigo (BPPV), vestibular neuritis, and Meniere's disease. These conditions are high-risk factors for vertigo. The prevalence of these risk factors is high globally.

Another significant cause for vertigo is vestibular neuritis that is an infection in the inner ears. The infection causes inflammation around the nerves that help the body sense balance. As a result, this infection causes a severe sensation of vertigo that can last for a couple of days and at times coupled with hearing loss.

Vestibular neuritis or BPPV may have a low prevalence rate individually. However, when combined, these risk factors of vertigo have a high prevalence rate. As a result, the growth of the global vertigo drugs market would be significant during the forecast period.

Increasing geriatric population

The prevalence of dizziness increases with age. Therefore. rising the geriatric population becomes the driving factor for the growth of the global vertigo drugs market. The aging world population is contributing to the rapid increase in the number of people with vertigo. Therefore, the increasing geriatric population will be driving the growth of the global vertigo drugs market during the forecast period.

Adversely effects of the available therapeutics

The market has the presence of a few approved therapeutics for the treatment of various risk factors of vertigo. These drugs are classified into phenothiazines, antihistamines, benzodiazepines and others. However. most of these therapeutics cause adverse effects when consumed for a long duration.

Key Players

  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries

Topics Covered

1. Executive Summary

2. Scope of the Report

3. Market Landscape

4. Market Sizing

5. Five Forces Analysis

6. Market Segmentation by Product

7. Customer Landscape

8. Geographic Landscape

9. Drivers and Challenges

10. Market Trends

11. Vendor Landscape

12. Vendor Analysis

For more information about this report visit https://www.researchandmarkets.com/research/t8pdz2/global_vertigo?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related Topics: Central Nervous System Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related Topics: Central Nervous System Drugs